Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

13 Mar 2023

Moving Towards Greater Recyclability in Drug Delivery – Sustainable Solutions b...

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions, Sustainability

Read More
13 Mar 2023

Nasal Delivery of Biologics: A Whole New Ball Game

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
5 Jan 2023

Case Study – Unidose Nasal Spray Pump for Epilepsy

Case Studies, Pharmaceutical, Product Solutions, Device Innovations, Market Insights

Read More
14 Dec 2022

Building Digital Solutions To Meet The Unique Therapeutic Needs of Patients

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 2 3 19
Back To Top